Solventum Corp Files 8-K on Governance and Compensation

Ticker: SOLV · Form: 8-K · Filed: 2024-05-17T00:00:00.000Z

Sentiment: neutral

Topics: governance, compensation, corporate-action

TL;DR

Solventum's 8-K details exec changes & pay; governance update.

AI Summary

Solventum Corporation, formerly part of 3M Company, filed an 8-K on May 13, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits related to these corporate governance and compensation matters.

Why It Matters

This filing provides insight into the corporate structure and executive compensation of Solventum Corporation, a newly independent entity, which is crucial for investors to understand its operational framework.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding governance and compensation, not indicating any immediate financial distress or significant operational risk.

Key Players & Entities

FAQ

What specific corporate governance changes are detailed in this 8-K filing?

The filing indicates changes related to the departure of directors or certain officers, the election of directors, and the appointment of certain officers.

What type of compensatory arrangements are mentioned in the filing?

The filing refers to compensatory arrangements of certain officers, though specific details are not provided in the summary text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 13, 2024.

What was Solventum Corporation's former name or affiliation?

Solventum Corporation was formerly part of 3M Company, with its former name being 3M Health Care Co.

What are the main items covered in this 8-K filing?

The main items covered are the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and financial statements and exhibits.

From the Filing

0001964738-24-000014.txt : 20240517 0001964738-24-000014.hdr.sgml : 20240517 20240517170747 ACCESSION NUMBER: 0001964738-24-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240513 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240517 DATE AS OF CHANGE: 20240517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solventum Corp CENTRAL INDEX KEY: 0001964738 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 922008841 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41968 FILM NUMBER: 24961213 BUSINESS ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 BUSINESS PHONE: 651-733-1110 MAIL ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 FORMER COMPANY: FORMER CONFORMED NAME: 3M Health Care Co DATE OF NAME CHANGE: 20230203 8-K 1 solv-20240513.htm 8-K solv-20240513 FALSE 0001964738 0001964738 2024-05-13 2024-05-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2024      Solventum Corporation (Exact name of registrant as specified in its charter) Delaware 001-41968 92-2008841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 3M Center, Building 275-6W 2510 Conway Avenue East Maplewood , MN 55144 (Address of Principal Executive Offices, including Zip code) ( 651 ) 733-1110 (Registrant’s telephone number, including area code) (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share SOLV New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 13, 2024, the Talent Committee (the “Committee”) of the Board of Directors of Solventum Corporation (the “Company”), in connection with the award of restricted stock units (“RSUs”) and performance shares (“PSUs”) to certain executive officers and directors of the Company, approved new forms of restricted stock unit award agreements (the “RSU Award Agreements

View on Read The Filing